NeuroPace, Inc. (NPCE) – What Are Analysts Saying About This Stock?

NeuroPace, Inc. (NASDAQ:NPCE) has been assigned an average recommendation of “Moderate Buy” from the ten brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $19.33.

NPCE has been the topic of a number of research analyst reports. Weiss Ratings lowered shares of NeuroPace from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 2nd. Guggenheim reissued a “neutral” rating on shares of NeuroPace in a report on Wednesday, July 29th. Raymond James Financial set a $21.00 target price on NeuroPace in a research report on Tuesday, September 15th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of NeuroPace in a research note on Wednesday, July 29th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of NeuroPace in a research note on Tuesday, September 15th.

Institutional Trading of NeuroPace

Institutional investors have recently modified their holdings of the company. First Light Asset Management LLC grew its holdings in NeuroPace by 16.3% during the second quarter. First Light Asset Management LLC now owns 2,861,167 shares of the company’s stock worth $45,464,000 after acquiring an additional 401,201 shares during the period. Bank of America Corp DE bought a new stake in NeuroPace in the second quarter worth about $322,000. Man Group plc acquired a new stake in NeuroPace in the 2nd quarter valued at about $1,336,000. Hsbc Holdings PLC acquired a new stake in NeuroPace in the 2nd quarter valued at about $420,000. Finally, Canada Pension Plan Investment Board acquired a new stake in NeuroPace in the 2nd quarter valued at about $351,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

NeuroPace Stock Performance

NPCE stock opened at $13.14 on Friday. The company has a market capitalization of $450.96 million, a P/E ratio of -23.05 and a beta of 1.86. The company has a 50-day simple moving average of $13.88 and a 200 day simple moving average of $15.16. NeuroPace has a fifty-two week low of $9.22 and a fifty-two week high of $19.60. The company has a quick ratio of 3.91, a current ratio of 4.94 and a debt-to-equity ratio of 4.97.

NeuroPace (NASDAQ:NPCE) last announced its earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. NeuroPace had a negative net margin of 19.34% and a negative return on equity of 105.64%. The firm had revenue of $22.83 million during the quarter, compared to analyst estimates of $22.61 million. Sell-side analysts predict that NeuroPace will post -0.67 earnings per share for the current fiscal year.

About NeuroPace

NeuroPace, Inc is a medical device company focused on developing and commercializing therapies for people with drug-resistant epilepsy. Its principal product is the RNS System, an implantable responsive neurostimulation device designed to detect abnormal electrical activity in the brain and deliver targeted stimulation intended to prevent or reduce seizures.

The RNS System includes an implanted neurostimulator, leads placed at or near seizure-onset areas, and a programming and data-management platform used by healthcare professionals.